Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

341.64 +11.47 (+3.47%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

62 63 Next >

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation ↗

January 17, 2025

Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer.

Via Benzinga

2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗

January 16, 2025

Via The Motley Fool

What Lies Ahead In 2025? Slower Growth, More Volatility ↗

January 14, 2025

As we move through 2025, the global economy and financial markets are facing a critical juncture.

Via Talk Markets

Topics Economy Stocks / Equities

Unpacking the Latest Options Trading Trends in Amgen ↗

January 13, 2025

Via Benzinga

Peering Into Amgen's Recent Short Interest ↗

January 13, 2025

Via Benzinga

Analyst Expectations For Amgen's Future ↗

January 02, 2025

Via Benzinga

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗

January 14, 2025

Via The Motley Fool

3 High-Yield Dividend Stocks to Buy in 2025 ↗

January 13, 2025

Via The Motley Fool

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Looking At Amgen's Recent Unusual Options Activity ↗

December 27, 2024

Via Benzinga

Spotlight on Amgen: Analyzing the Surge in Options Activity ↗

December 23, 2024

Via Benzinga

2 Excellent Dividend Stocks to Buy on the Dip ↗

December 23, 2024

Via The Motley Fool

UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients ↗

January 06, 2025

Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited treatment options.

Via Benzinga

Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗

January 04, 2025

Via The Motley Fool

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

January 03, 2025

Via The Motley Fool

Topics Stocks

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

January 03, 2025

Via Benzinga

Dissecting Our Discipline ↗

January 02, 2025

All portfolio managers practice a stock-picking discipline in which they make choices.

Via Talk Markets

Topics Stocks / Equities

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025 ↗

December 31, 2024

In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall.

Via Benzinga

Topics Stocks

3 Worst Performing Dow Jones Stocks In 2024 ↗

December 29, 2024

The Dow Jones Industrial Average will finish 2024 with a positive return. The index has climbed about 24% this year.

Via Talk Markets

Topics Stocks Stocks / Equities

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 26, 2024

Via Benzinga

Schwab US Dividend Equity ETF Reverses In December: What's Going On? ↗

December 23, 2024

The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund:

Via Benzinga

Topics ETFs

What's Going On With Amgen Stock On Friday? ↗

December 20, 2024

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing.

Via Benzinga

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. ↗

December 20, 2024

Eli Lilly and Viking Therapeutics jumped on Novo's setback.

Via Investor's Business Daily

10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak ↗

December 19, 2024

Investors shrugged off the meltdown on Thursday. A few Dow laggards rebounded.

Via Investor's Business Daily

Topics Stocks

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease ↗

December 16, 2024

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

Via Investor's Business Daily

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.